Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3044% below fair value
$2.90−0.16 (-5.23%)
Close on Nov 20, 2026Market cap $233.66MP/E 12.6Yield –
Protalix BioTherapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Protalix BioTherapeutics's free cash flow for the twelve months ending Jun 30, 2026 was $7.67M. For fiscal 2025 it was -$13.63M, down 284.4% from the year before. The highest annual figure on record is $38.26M in fiscal 2009.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.63M | -284.4% |
| FY2024 | Dec 31, 2024 | $7.39M | – |
| FY2023 | Dec 31, 2023 | -$2.47M | – |
| FY2022 | Dec 31, 2022 | -$25.63M | – |
| FY2021 | Dec 31, 2021 | -$11.74M | – |
| FY2020 | Dec 31, 2020 | -$26.76M | – |
| FY2019 | Dec 31, 2019 | -$19.99M | – |
| FY2018 | Dec 31, 2018 | -$8.43M | – |
| FY2017 | Dec 31, 2017 | -$10.97M | – |
| FY2016 | Dec 31, 2016 | -$32.95M | – |
| FY2015 | Dec 31, 2015 | -$24.75M | – |
| FY2014 | Dec 31, 2014 | -$30.07M | – |
| FY2013 | Dec 31, 2013 | -$32.54M | – |
| FY2012 | Dec 31, 2012 | -$1.43M | – |
| FY2011 | Dec 31, 2011 | -$29.28M | – |
| FY2010 | Dec 31, 2010 | -$46.32M | -221.1% |
| FY2009 | Dec 31, 2009 | $38.26M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.99M | – |
| Q1 FY2026 | Mar 31, 2026 | $21.26M | – |
| Q4 FY2025 | Dec 31, 2025 | $1.63M | -54.4% |
| Q3 FY2025 | Sep 30, 2025 | -$4.23M | -205.3% |
| Q2 FY2025 | Jun 30, 2025 | -$5.66M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.36M | -249.4% |
| Q4 FY2024 | Dec 31, 2024 | $3.57M | +6.6% |
| Q3 FY2024 | Sep 30, 2024 | $4.02M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.78M | -179.3% |
| Q1 FY2024 | Mar 31, 2024 | $3.59M | – |
| Q4 FY2023 | Dec 31, 2023 | $3.35M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.34M | – |
| Q2 FY2023 | Jun 30, 2023 | $4.77M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.25M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.82M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.26M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.48M | -220.0% |
| Q1 FY2022 | Mar 31, 2022 | -$6.06M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.54M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.22M | – |
| Q2 FY2021 | Jun 30, 2021 | $6.24M | – |
| Q1 FY2021 | Mar 31, 2021 | -$10.22M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.83M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.18M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.72M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.62M | -126.7% |
| Q2 FY2019 | Jun 30, 2019 | -$5.21M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.45M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.19M | -124.2% |
| Q3 FY2018 | Sep 30, 2018 | $13.54M | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.11M | – |
| Q1 FY2018 | Mar 31, 2018 | -$9.66M | – |
| Q4 FY2017 | Dec 31, 2017 | $17.30M | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.68M | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.94M | – |
| Q1 FY2017 | Mar 31, 2017 | -$8.65M | – |
| Q4 FY2016 | Dec 31, 2016 | -$7.46M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.60M | – |
| Q2 FY2016 | Jun 30, 2016 | -$12.02M | – |
See a number that looks wrong?